{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:44:59Z","timestamp":1744177499366},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T00:00:00Z","timestamp":1336694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>In contrast to <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101 infection, little is known about the natural disease course of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20102 and its response to antiretrovirals (<jats:styled-content style=\"fixed-case\">ARVs<\/jats:styled-content>). We describe a cohort of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20102\u2010infected patients, focusing on the method of diagnosis, <jats:styled-content style=\"fixed-case\">ARV<\/jats:styled-content> treatment and complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Through a retrospective review of medical records at our centre, we identified 12 patients with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20102 infection in our clinic population (1400 active patients) who received care between 2002 and 2011. We summarized clinical characteristics, <jats:styled-content style=\"fixed-case\">ARV<\/jats:styled-content> treatment and outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven of the patients were male and five were female. All patients were born in West African countries. The mode of transmission was heterosexual intercourse in 11 patients, and injecting drug use in one patient. The median CD4 count at the time of diagnosis was 668 cells\/\u03bcL (range 23 to 1546 cells\/\u03bcL). <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20102 quantitative viral load measurements were not uniformly available to clinicians. Four patients were treated with protease inhibitor\u2010based regimens, with a mean increase in CD4 count of 183 cells\/\u03bcL (range 43 to 341 cells\/\u03bcL). The other eight patients have been observed off <jats:styled-content style=\"fixed-case\">ARVs<\/jats:styled-content>. Two patients experienced complications from <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>, one patient had <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> encephalopathy and molluscom contagiosum, and another had microsporidiosis infection in the setting of <jats:styled-content style=\"fixed-case\">AIDS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results support those of previous studies indicating that <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20102 has a more indolent disease course than <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101, with a spectrum of disease ranging from asymptomatic to <jats:styled-content style=\"fixed-case\">AIDS<\/jats:styled-content>. Development of a reliable quantitative <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20102 viral load assay to guide management is needed. Further research studies are needed to establish the best time to start <jats:styled-content style=\"fixed-case\">ARV<\/jats:styled-content> treatment in <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20102\u2010infected patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2012.01025.x","type":"journal-article","created":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T04:47:46Z","timestamp":1336711666000},"page":"115-119","source":"Crossref","is-referenced-by-count":4,"title":["<scp>HIV<\/scp>\u20102 infection in Providence, Rhode Island from 2002 to 2011"],"prefix":"10.1111","volume":"14","author":[{"given":"BL","family":"Hollenbeck","sequence":"first","affiliation":[{"name":"Department of Medicine Alpert Medical School of Brown University  Providence RI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CG","family":"Beckwith","sequence":"additional","affiliation":[{"name":"Department of Medicine Alpert Medical School of Brown University  Providence RI USA"},{"name":"Department of Medicine Division of Infectious Diseases The Immunology Center at The Miriam Hospital  Providence RI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/597504"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/657117"},{"key":"e_1_2_7_4_1","first-page":"985","article-title":"HIV\u20102 Infection Surveillance \u2013 United States, 1987\u20132009","volume":"60","author":"Torian LV","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_7_5_1","first-page":"462","article-title":"The natural history of HIV\u20101 and HIV\u20102 infections in adults in Africa: a literature review","volume":"82","author":"Jaffar S","year":"2004","journal-title":"Bull World Health Organ"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00154-09"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0792"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200317003-00007"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.03.011"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.02.324"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.11.008"},{"key":"e_1_2_7_12_1","unstructured":"Priority Interventions.HIV\/AIDS prevention treatment and care in the health sector. World Health Organization. July2010. Available athttp:\/\/whqlibdoc.who.int\/publications\/2010\/9789241500234_eng.pdf(accessed 30 April 2012)."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir123"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2010.00889.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq248"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00619.x"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2012.01025.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2012.01025.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T09:09:11Z","timestamp":1697360951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2012.01025.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,11]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1111\/j.1468-1293.2012.01025.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2012.01025.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,11]]}}}